skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Ocaratuzumab (Code C2524)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Ocaratuzumab

Definition: An Fc-engineered monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ocaratuzumab specifically binds to CD20 antigen (B1), preventing mitogen-induced B-cell proliferation; inhibiting B-cell differentiation; and promoting antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis of B cells expressing CD20. The Fc portion of this monoclonal antibody has been engineered to possess a higher binding affinity for variant Fc receptors on T helper cells, resulting in an augmentation of the anti-tumor immune response. Because of Fc engineering, this agent may be significantly more potent than rituximab in inducing B cell-directed ADCC. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development.

Display Name: Ocaratuzumab

Label: Ocaratuzumab

NCI Thesaurus Code: C2524 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1831936  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Anti-CD20 Monoclonal Antibody AME-133v
LY 2469298
MoAb CD20
monoclonal antibody, CD20

External Source Codes: 
CAS Registry Number 1169956-08-4 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 500055
PDQ Open Trial Search ID 500055 (check for NCI PDQ open clinical trial info)
UMLS CUI C1831936

Other Properties:
     Name Value (qualifiers indented underneath)
code C2524
Contributing_Source CTRP
Legacy_Concept_Name Monoclonal_Antibody_CD20
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom